Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000905148-25-000694
Filing Date
2025-02-14
Accepted
2025-02-14 16:58:02
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 28386
2 jointfilingagreement.htm EX-99.1 8157
  Complete submission text file 0000905148-25-000694.txt   38236
Mailing Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901
Business Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

EIN.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Subject) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94871 | Film No.: 25630444
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)